The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Danese Silvio) > The Future of Biosi...

The Future of Biosimilars : Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Kim, HoUng (author): Celltrion Healthcare, Incheon, Republic of Korea; Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea

Alten, Rieke (author): Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany

Avedano, Luisa (author): European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium

Dignass, Axel (author): Department of Medicine 1, Agaplesion Markus Hospital, Frankfurt am Main, Germany

Gomollon, Fernando (author): Gastroenterology Unit, Clinical University Hospital Lozano Bless IIS Aragón, Zaragoza, Spain

Greveson, Kay (author): Centre for Gastroenterology, Royal Free Hospital, London, UK

Halfvarson, Jonas, 1970- (author): Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology

Irving, Peter M. (author): IBD Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Jahnsen, Jørgen (author): Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Lakatos, Peter L. (author): Division of Gastroenterology, McGill University, Montreal QC, Canada; 1st Department of Medicine, Semmelweis University, Budapest, Hungary

Lee, JongHyuk (author): Department of Pharmaceutical Engineering, College of Life and Health Science, Hoseo University, Asan, Republic of Korea

Makri, Souzi (author): Cyprus League Against Rheumatism, Nicosia, Cyprus

Parker, Ben (author): Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Peyrin-Biroulet, Laurent (author): Inflammatory Bowel Disease Unit, Nancy University Hospital, Allée du Morvan, France

Schreiber, Stefan (author): Department Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany

Simoens, Steven (author): Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

Westhovens, Rene (author): Department of Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Rheumatology University Hospital Leuven, Leuven, Belgium

Danese, Silvio (author): Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy

Jeong, Ji Hoon (author): Department of Pharmacology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea

show less...

(creator_code:org_t)

2020-01-30
2020
English.
In: Drugs. - : Adis International. - 0012-6667 .- 1179-1950. ; 80:2, s. 99-113

Related links:: https://doi.org/10.1...; show more...; https://link.springe...; https://urn.kb.se/re...; https://doi.org/10.1...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.

Find in a library

Drugs (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Pharmacology and ...

Articles in the publication: Drugs

By the university: Örebro University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

The Future of Biosimilars : Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Subject headings

Publication and Content Type

Find in a library

To the university's database

Find more in SwePub

Search outside SwePub